Puma's neratinib gets by in NSCLC, with a little help from Imodium
This article was originally published in Scrip
Puma Biotechnology's novel targeted anticancer neratinib appears to have found a new therapeutic setting on the basis of Phase II data presented at a late-breaking oral session at the recent ESMO meeting that suggest potential in non-small cell lung cancer.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.